Monitoring people for adverse effects of medicines: The Adverse Drug Reaction (ADRe) Profile

# Benefits and harms of medicines: the problem

* Medication-related harm accounts for ~50% of preventable harm during healthcare delivery & costs ~$42 billion p.a. (WHO 2022).
* ADRs cause 5-8% unplanned UK hospital admissions (NICE 2015):
	+ 8.7% in older people (Oscanoa et al 2017)
	+ 18.4% medical admissions (Osanlou et al 2022)
	+ most ADRs predictable and avoidable
* Voluntary reporting of serious ADRs omits 94% (Hazel & Shakir 2006),

<1% of GI haemorrhages are reported in UK (Shuttleworth et al 2023).

* “Definitely avoidable” ADRs cause 712 deaths directly, and contribute to another 1,708, costing NHS ~£98.5 million p.a. (Elliott et al 2018).
* Potentially inappropriate prescribing doubles costs in 1° care (Robinson et al 2022): 1 preventable ADR costs €2,851-9,015 (Formica et al., 2018).
* Hospital admissions to manage ADRs cost £490.716 / month in 1 UK hospital ~£2.2bn pa to NHS England (Osanlou et al 2022)\*.
* Non-indicated, unnecessary prescribing of dependency-forming medicines costs NHS England ~£500,000 p.a. (Davies et al 2022).

\* The total NHS budget for England 2023 was £163bn (Health Foundation 2024)

# What ADRe does:

# ADRe checks patients for potential ADRs and offers decision support.

In routine practice, ADRe:

1. **Improves patients’ lives** e.g. reduces pain, dyspnoea, sedation
2. **Assists in early identification** of serious problems, some wholly or partly due to ADRs e.g. pancreatitis, falls, chest pain
3. **Identifies live-threatening conditions** in ~10% participants
4. **Supports and documents medication reviews**
5. Ensures compliance with policies & guidelines.

ADRe has been tested in clinical trials, observation, before and after and follow up studies. We hope to work with organisations digitising patient records, developing monitoring devices or recording ADRs.

Please visit our website: [**http://www.swansea.ac.uk/adre/**](http://www.swansea.ac.uk/adre/)

Jordan S, Prout H, Carter N, Dicomidis J, Hayes J, Round J, Carson-Stevens A. (2021) Nobody ever questions—Polypharmacy in care homes: A mixed methods evaluation of a multidisciplinary medicines optimisation initiative. PLOS ONE 16(1): e0244519. <https://doi.org/10.1371/journal.pone.0244519>

Jordan,S., Logan,V., Turner,A., & Hughes,D.Using nurse-led patient monitoring to avoid medicines-related harm.*Nursing Standard*, doi:10.7748/ns.2021.e11770. 28.6.21

Jordan S., Jones E., Komninou S., Loane M., Damase-Michel C. Families need support to reduce the risks of adverse drug reactions from breastfeeding. The Pharmaceutical Journal, PJ, December 2022, Vol 309, No 968;309(7968):: DOI:10.1211/PJ.2022.1.166126

Logan, V., Bamsey, A., Carter, N., Hughes, D., Turner, A. & Jordan, S. (2022). Clinical Impact of Implementing a Nurse-Led Adverse Drug Reaction Profile in Older Adults Prescribed Multiple Medicines in UK Primary Care: A Study Protocol for a Cluster-Randomised Controlled Trial. *Pharmacy*; 10(3):52.

Logan, V, Keeley, S, Akerman, K, De Baetselier E, Dilles, T, Griffin N, Matthews L, Van Rompaey B, Jordan S.  Did we do everything we could have? Nurses’ contributions to medicines optimization: A mixed‐methods study. *Nurs Open*. 2021; 8: 592– 606. <https://doi.org/10.1002/nop2.664>

Jordan S, Banner T, Gabe-Walters M., Mikhail J., Panes G., Round J., Snelgrove S., Storey M., Hughes D for the Medicines Management Group (2019) Nurse-led medicines’ monitoring in care homes, implementing the Adverse Drug Reaction (ADRe) Profile improvement initiative for Mental Health Medicines: an observational and interview study. Plos One. 14(9): e0220885. <https://doi.org/10.1371/journal.pone.0220885>

Jordan S & Hughes D 2019 Clozapine deaths: monitoring adverse drug reactions. BMJ 2019;364:l482 doi: 10.1136/bmj.l482

Jordan S, Gabe-Walters M, Watkins A, Humphreys I, Newson L, Snelgrove S et al. Nurse-Led Medicines' Monitoring for Patients with Dementia in Care Homes: A Pragmatic Cohort Stepped Wedge Cluster Randomised Trial. PLOS ONE. 2015;10(10):e0140203.

Jordan S, Banner T, Gabe-Walters M the Medicines Management Group*, et al* Nurse-led medicines’ monitoring in care homes study protocol: a process evaluation of the impact and sustainability of the adverse drug reaction (ADRe) profile for mental health medicines *BMJ Open*2018;**8:**e023377. doi: 10.1136/bmjopen-2018-023377

Jordan S. Managing Adverse Drug Reactions: An Orphan Task. Developing Nurse-Administered Evaluation  Checklists  Journal of Advanced Nursing . 2002, 38(5):437-48

Jordan S, Logan PA, Panes G, Vaismoradi M, Hughes D. Adverse Drug Reactions, Power, Harm Reduction, Regulation and the ADRe Profiles. Pharmacy (Basel). 2018 Sep 18;6(3). pii: E102. doi: 10.3390/pharmacy6030102. PubMed PMID: 30231573.

*Gabe M, Jordan S. Development and clinical gains of nurse-led medication monitoring profiles. J Nurs Manag. 2014;22(3):331-349.*

Gabe M, Murphy F, Davies G, Russell I, Jordan S. Medication Monitoring in a Nurse-Led Respiratory Outpatient Clinic: Pragmatic Randomised Trial of the West Wales Adverse Drug Reaction Profile. PLoS ONE. 2014;9(5):e96682. DOI: 10.1371/journal.pone.0096682

Jordan S, Hardy B, Coleman M. Medication management: an exploratory study into the role of community mental health nurses. J Adv Nurs. 1999;29(5):1068-1081.

Jordan S, Knight J, Pointon D. Monitoring adverse drug reactions: scales, profiles, and checklists. Int Nurs Rev. 2004;51(4):208-221.

Jordan S. and Hughes D. 2000 Community Teamwork is key to monitoring the side effects of medication. *Nursing Times/ BMJ inaugural joint issue* : 96 : 15 : 39-40

Hughes, D.; Jordan, M.; Logan, P.A.; Willson, A.; Snelgrove, S.; Storey, M.; Vaismoradi, M.; Jordan, S. Looking for the “Little Things”: A Multi-Disciplinary Approach to Medicines Monitoring for Older People Using the ADRe Resource. *Geriatrics* **2020**, *5*, 79. <https://www.mdpi.com/2308-3417/5/4/79>

Jones R., Moyle C. Jordan S. (corresponding author) 2016 Nurse-led Medicines Monitoring: a before and after study to examine the clinical impact of the West Wales Adverse Drug Reaction Profile in a Crisis Resolution Home Treatment service. *Nursing Standard*. 31, 14, 42-53. doi: 10.7748/ns.2016.e10447

Jordan S, Gabe M, Newson L, Snelgrove S, Panes G, Picek A, Russell IT, Dennis M. (2014) "Medication Monitoring for People with Dementia in Care Homes: the Feasibility and Clinical Impact of Nurse-led monitoring," The Scientific World Journal, vol. 2014, Article ID 843621, 11 pages, 2014. doi:10.1155/2014/843621.

## References and Bibliography

Beijer HJ, de Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm World Sci. 2002 Apr;24(2):46-54. doi: 10.1023/a:1015570104121. PMID: 12061133.

Brøgger-Mikkelsen M, Zibert JR, Andersen AD, Lassen U, Hædersdal M, Ali Z, Thomsen SF. Changes in key recruitment performance metrics from 2008-2019 in industry-sponsored phase III clinical trials registered at ClinicalTrials.gov. PLoS One. 2022 Jul 26;17(7):e0271819. doi: 10.1371/journal.pone.0271819. PMID: 35881593; PMCID: PMC9321424.

 Davies, J., Cooper, R. E., Moncrieff, J., Montagu, L., Rae, T., & Parhi, M. (2022). The costs incurred by the NHS in England due to the unnecessary prescribing of dependency-forming medications. *Addictive Behaviors, 125*, 107143–107143. <https://doi.org/10.1016/j.addbeh.2021.107143>

 Elliott, R. A., Camacho, E., Jankovic, D., Sculpher, M. J., & Faria, R. (2021). Economic analysis of the prevalence and clinical and economic burden of medication error in England. *BMJ Quality & Safety, 30*(2), 96–105. <https://doi.org/10.1136/bmjqs-2019-010206>

Formica, D., Sultana, J., Cutroneo, P.M., Lucchesi, S., Angelica, R., Crisafulli, S., Ingrasciotta, Y., Salvo, F., Spina, E. & Trifiro, G. (2018) The economic burden of preventable adverse drug reactions: a systematic review of observational studies. *Expert Opinion on Drug Safety. 17* (7). 681-695. https://doi.org/10.1080/14740338.2018.1491547

Gurwitz JH, Field TS, Harrold LR *et al* (2003) Incidence and preventability of adverse drug events among older persons in the ambulatory setting. *Journal of the American Medical Association.* 289, 9, 1107-1116.

 Hazell, L., & Shakir, S. A. . (2006). Under-Reporting of Adverse Drug Reactions: A Systematic Review. *Drug Safety, 29*(5), 385–396. <https://doi.org/10.2165/00002018-200629050-00003>

Health Foundation 2024 Health Care Funding <https://www.health.org.uk/publications/long-reads/health-care-funding#:~:text=Planned%20NHS%20England%20RDEL%20in,small%20increase%20of%200.2%25>). Accessed 8.7.24

Howard RL, Avery AJ, Howard PD, Partridge M (2003) Investigation into the reasons for preventable drug related admissions to a medical admissions’ unit: observational study. *Quality and Safety in Health Care.* 12, 4, 280-285.

King’s Fund [https://www.kingsfund.org.uk/insight-and-analysis/data-and-charts/nhs-budget-nutshell accessed 1.7.24](https://www.kingsfund.org.uk/insight-and-analysis/data-and-charts/nhs-budget-nutshell%20accessed%201.7.24)

NHS Resolution. Annual report and accounts 2022-23. July 2023. <https://resolution.nhs.uk/wp-content/uploads/2023/07/NHS-Resolution-Annual-report-and-accounts-2022_23-3.pdf>.

NICE Medicines & Prescribing Centre 2015 Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes. NICE guideline 5. NICE, London.<http://www.nice.org.uk/guidance/ng5/evidence/full-guideline-6775454>

Osanlou R, Walker L, Hughes DA, Burnside G, Pirmohamed M. Adverse drug reactions, multimorbidity and polypharmacy: a prospective analysis of 1 month of medical admissions. BMJ Open. 2022 Jul 4;12(7):e055551. doi: 10.1136/bmjopen-2021-055551. PMID: 35788071; PMCID: PMC9255409.

 Oscanoa, T. J., Lizaraso, F., & Carvajal, A. (2017). Hospital admissions due to adverse drug reactions in the elderly. A meta-analysis. European Journal of Clinical *Pharmacology, 73*(6), 759–770. https://doi.org/10.1007/s00228-017-2225-3

Pirmohamed M, James S, Meakin S *et al* (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. *British Medical Journal.* 329, 7456, 15-19.

 Robinson, E. G., Hedna, K., Hakkarainen, K. M., & Gyllensten, H. (2022). Healthcare costs of adverse drug reactions and potentially inappropriate prescribing in older adults: a population-based study. *BMJ Open, 12*(9), e062589–e062589. <https://doi.org/10.1136/bmjopen-2022-062589>

 Shuttleworth, P., Baker, J., & Clark, E. (2023). Under-reporting of gastrointestinal bleeding associated with anticoagulant use using the UK Yellow Card Scheme. *International Journal of Clinical Pharmacy, 45*(4), 1014–1018. <https://doi.org/10.1007/s11096-023-01601-0>

WHO (World Health Organisation). (2022). *The Third Global Patient Safety Challenge.* Retrieved September 20, 2023, from <https://www.pslhub.org/learn/organisations-linked-to-patient-safety-uk-and-beyond/international-patient-safety/who/the-third-who-global-patient-safety-challenge-medication-without-harm-r7406/>

WHO / World Health Organization. (‎2019)‎. Medication safety in polypharmacy: technical report. World Health Organization. <https://apps.who.int/iris/handle/10665/325454>.

WHO 2023 Medication without harm: policy brief. Geneva: World Health Organization; 2023. Licence: CC BY-NC-SA 3.0 IGO. <https://iris.who.int/bitstream/handle/10665/376212/9789240062764-eng.pdf?sequence=1>